CureApp: Digital Therapeutic App for Hypertension Receives Insurance Coverage, Sales of the Service to Medical Institutions Across Japan Launch on September 1
Retrieved on:
Wednesday, November 2, 2022
Technology, Mobile, Wireless, Health, Apps, Applications, Research, Telemedicine, Virtual Medicine, Medical Devices, Software, Managed Care, Hospitals, Health Technology, Health Insurance, Science, Clinical Trials, Breast cancer, EHJ, Digital therapeutics, Research, Time, Prescription, SANKYO, Head, Randomized controlled trial, HT, Insurance, Government, Safety, Behavior, PMID, Guideline, Chūō-ku, Education, Health education, Digital, Company, Woman, Patient, Single-frequency network, Medtech, Multimedia, Nicotine, Smoking, Therapy, National Healthcare, Pharmaceutical industry, Medical device, Hypertension
Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.
Key Points:
- Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.
- In April 2022, CureApp HT was the first digital therapeutics app for hypertension to receive government approval in the world, and the app has been covered by insurance since September 1.
- This marks the first case of a DTx treatment solution being covered by insurance in the field of hypertension in the world.
- Looking ahead, we will look to sequentially rolling out this Japanese-developed digital health solution worldwide based on the model established in Japan.